母体供者在使用移植后环磷酰胺的半相合移植中的风险:受者性别的作用
Maternal donor risk in haploidentical transplant with post-transplant cyclophosphamide: the role of recipient sex
该研究分析了母体供者在使用移植后环磷酰胺的半相合移植中的风险,发现受者性别可能影响结果,但具体机制尚需进一步研究。数据来自CIBMTR数据库,使用灰度检验和Kaplan-Meier方法评估移植后并发症和生存率。
Pediatric haploidentical hematopoietic cell transplantation (haplo-HCT) relies primarily on parental donors [1]. Maternal donors are linked to increased chronic graft-versus-host disease (cGVHD) [1, 2] and inferior survival [2] in T-cell-replete settings with post-transplant cyclophosphamide (PTCy). Whether these effects differ by recipient sex remains unclear. Male recipients might be uniquely at risk due to pre-existing maternal sensitization against paternal HLA antigens and minor histocompatibility antigens expressed by the Y chromosome (H-Y) [3]. Further investigation is needed to understand how maternal donor and recipient sex influence outcomes in PTCy haplo-HCT for pediatric leukemia.
Detailed methods are provided in Supplement 1. Data were extracted from the Center for International Blood and Marrow Transplant Research (CIBMTR) dataset P-6144 [4]. Patients ≤21 years with acute leukemia undergoing parental-donor PTCy haplo-HCT between 2013 and 2021 were grouped by allo-immunization risk. Gray’s test compared cumulative incidences of acute GVHD (aGVHD), cGVHD requiring immunosuppressive therapy (IST), relapse, and treatment-related mortality (TRM), accounting for competing risks. Overall survival (OS), relapse-free survival (RFS), and GVHD-free, relapse-free survival (GRFS) [5] were assessed by the Kaplan–Meier method and compared via the log-rank test. Cause-specific Cox proportional hazards models assessed the impact of donor-recipient relationship, adjusting for age, comorbidity, disease type/status, conditioning intensity, and graft source (Supplementary Tables 1–4). All analyses were performed using R statistical software version 4.5.3.
Subscribe to this journal
Receive 12 print issues and online access
251.40 € per year only 20.95 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Data availability
The deidentified individual participant data and a data dictionary for the dataset analyzed in this study are publicly available for immediate download from the Center for International Blood and Marrow Transplant Research (CIBMTR) at https://cibmtr.org/CIBMTR/Resources/Publicly-Available-Datasets. Access is governed by the CIBMTR’s “Terms of Use and Conditions”; downloading the dataset implies agreement to these terms.
Code availability
R code used to generate the analyses is available from the corresponding author upon reasonable request.
References
Liberio N, Allbee-Johnson M, Ahn KW, Moskop A, Phelan R, Shaw BE, et al. Optimizing haploidentical donor selection for pediatric hematopoietic cell transplant. J Clin Oncol. 2026;44:1003–15.
Rocha V, Arcuri LJ, Seber A, Colturato V, Zecchin VG, Kuwahara C, et al. Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia. Bone Marrow Transpl. 2021;56:3042–8.
Popli R, Sahaf B, Nakasone H, Lee JYY, Miklos DB. Clinical impact of H-Y alloimmunity. Immunol Res. 2014;58:249–58.
Mehta RS, Schmidt G, Williams K, Patel SA, Schetelig J, Savani B, et al. Choosing between HLA-mismatched unrelated and haploidentical donors: donor age considerations. Transpl Cell Ther. 2025;31:680–92.
Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite endpoint of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–8.
De Nardi L, Simeone R, Torelli L, Maestro A, Zanon D, Barbi E, et al. Pediatric males receiving hematopoietic stem cell transplant lose their male disadvantage in disease risk after the procedure: a retrospective observational study. Int J Cancer. 2022;151:191–9.
Stern M, Brand R, De Witte T, Sureda A, Rocha V, Passweg J, et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transpl. 2008;8:2149–57.
Nakasone H, Tian L, Sahaf B, Kawase T, Schoenrock K, Perloff S, et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood. 2015;125:3193–201.
Gratwohl A, Brand R, Apperley J, van Biezen A, Bandini G, Devergie A, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100:3877–86.
Shimoni A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, et al. The association of graft-versus-leukemia effect and graft-versus-host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. Bone Marrow Transpl. 2022;57:384–90.
Sanz J, Ferhat AT, Raiola AM, Blaise D, Arat M, Koc Y, et al. Donor selection in PTCy haploidentical transplant for acute lymphoblastic leukemia: a study from the ALWP of the EBMT. Bone Marrow Transpl. 2026;61:166–71.
Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8:2332–41.
Ruggeri L, Eikema D-J, Bondanza A, Noviello M, Van Biezen A, De Wreede LC, et al. Mother donors improve outcomes after HLA haploidentical transplantation: A study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. Transpl Cell Ther. 2022;28:206.e1–206.e6.
Van Kampen CA, Versteeg-Vd Voort Maarschalk MFJ, Langerak-Langerak J, Roelen DL, Claas FHJ. Kinetics of the pregnancy-induced humoral and cellular immune response against the paternal HLA class I antigens of the child. Hum Immunol. 2002;63:452–8.
Kinder JM, Turner LH, Stelzer IA, Miller-Handley H, Burg A, Shao TY, et al. CD8+ T cell functional exhaustion overrides pregnancy-induced fetal antigen alloimmunization. Cell Rep. 2020;31:107784.
Acknowledgements
This dataset was collected by the Center for International Blood and Marrow Transplant Research (CIBMTR) which is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; 75R60222C00011 from the Health Resources and Services Administration; National Marrow Donor Program (NMDP); and the Medical College of Wisconsin. We acknowledge the CIBMTR staff for making the dataset publicly available. CIBMTR had no role in the study design, data analysis, interpretation of results, or manuscript preparation. The study was not reviewed by CIBMTR and does not represent its views.
Funding
The dataset for the study was provided by the Center for International Blood and Marrow Transplant Research (CIBMTR) which is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; 75R60222C00011 from the Health Resources and Services Administration; N00014-21-1-2954 and N00014-23-1-2057 from the Office of Naval Research; the National Marrow Donor Program; and the Medical College of Wisconsin. We acknowledge that European Union patient-level data is redacted. Our study utilized a publicly available, de-identified dataset provided by the CIBMTR. The funding sources listed supported the CIBMTR for the collection and maintenance of this dataset. As such, the funders had no role in the design and conduct of our specific study; collection, management, analysis, and interpretation of the data; preparation, review.
Author information
Authors and Affiliations
Division of Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
Rachel E. Granberg, Melissa Mavers, Shalini Shenoy, Jeffrey J. Bednarski & Thomas Pfeiffer
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
Feng Gao
Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children’s Research Hospital, Memphis, TN, USA
Akshay Sharma
Authors
- Rachel E. Granberg
- Feng Gao
- Melissa Mavers
- Shalini Shenoy
- Jeffrey J. Bednarski
- Akshay Sharma
- Thomas Pfeiffer
Contributions
REG and TP conceived the project and designed the study. FG, TP, and REG performed statistical analysis. All authors (REG, FG, MM, SS, JJB, AS, and TP) contributed to the interpretation of the results and provided critical intellectual input. REG, FG, and TP prepared the figures and tables. REG and TP wrote the manuscript. All authors (REG, FG, MM, SS, JJB, AS, and TP) reviewed, edited, and approved the manuscript.
Corresponding author
Correspondence to Thomas Pfeiffer.
Ethics declarations
Competing interests
AS has received consultant fees from Medexus Inc, Vertex Pharmaceuticals, Sangamo Therapeutics, Editas Medicine, BioLineRx, Pfizer, Gamida Cell, RGenta Therapeutics, Bristol Myers Squibb and Beam Therapeutics; is a medical monitor for the CSIDE clinical trial for which he receives financial compensation; has received honoraria from Blackwood CME and PeerView Institute for Medical Education; and is the St. Jude Children’s Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287), Novartis Pharmaceuticals (NCT04443907), and Beam Therapeutics (NCT05456880). The industry sponsors provide funding for the clinical trial, which includes salary support paid to the institution. AS has no direct financial interest in these therapies. These conflicts are managed through the compliance office at St. Jude Children’s Research Hospital in accordance with their conflict-of-interest policy. All other authors have no conflicts or financial interests to disclose.
Ethics approval and consent to participate
All methods were performed in accordance with the relevant guidelines and regulations, including the ethical principles of the Declaration of Helsinki. This study is a secondary analysis of a de-identified, publicly available dataset released by the Center for International Blood and Marrow Transplant Research (CIBMTR; https://cibmtr.org/CIBMTR/Resources/Publicly-Available-Datasets). The analytic cohort was originally assembled for the study by Mehta et al., “Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations” (Mehta et al., Transplant Cell Ther, 2025), and derived from the CIBMTR research database (NCT01166009). The CIBMTR conducts its research in compliance with all applicable federal regulations for the protection of human research participants and international laws and ethical guidelines governing the privacy and human rights of participants. The CIBMTR research database from which these data are derived was reviewed and approved by the Institutional Review Board of the NMDP (Registration # IRB00001253). The governing protocol is registered at ClinicalTrials.gov under NCT01166009 (research database). Because this analysis used a de-identified, publicly available dataset, it did not constitute human subjects research and did not require separate institutional review board approval. Informed consent was obtained from all participants. Specifically, all patients (or their legal guardians) provided written informed consent for participation in research at the time of enrollment into the NMDP Institutional Review Board–approved CIBMTR research database. Because the dataset analyzed in this study was de-identified and publicly available, no additional informed consent was required for this secondary analysis.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Granberg, R.E., Gao, F., Mavers, M. et al. Maternal donor risk in haploidentical transplant with post-transplant cyclophosphamide: the role of recipient sex. Leukemia (2026). https://doi.org/10.1038/s41375-026-03179-8
Received: 17 June 2026
Revised: 25 September 2026
Accepted: 07 October 2026
Published: 05 November 2026
Version of record: 05 November 2026
DOI: https://doi.org/10.1038/s41375-026-03179-8
来源:Nature 健康护理主题 · nature.com